Advertisement
UK markets close in 4 hours 8 minutes
  • FTSE 100

    8,083.35
    +38.54 (+0.48%)
     
  • FTSE 250

    19,796.29
    -3.43 (-0.02%)
     
  • AIM

    754.89
    +0.02 (+0.00%)
     
  • GBP/EUR

    1.1638
    +0.0010 (+0.08%)
     
  • GBP/USD

    1.2440
    -0.0012 (-0.10%)
     
  • Bitcoin GBP

    53,400.39
    +223.84 (+0.42%)
     
  • CMC Crypto 200

    1,435.24
    +11.14 (+0.78%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.73
    -0.63 (-0.76%)
     
  • GOLD FUTURES

    2,328.70
    -13.40 (-0.57%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,193.41
    +55.76 (+0.31%)
     
  • CAC 40

    8,133.45
    +27.67 (+0.34%)
     

Teva Announces Launch of Generic Version of Uceris in US

Teva Announces Launch of Generic Version of Uceris in US

On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.